Phase 1b study of U3-1287 in combination with trastuzumab plus paclitaxel in patients with HER2-positive metastatic breast cancer (MBC)
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 21 Jul 2017
At a glance
- Drugs Patritumab (Primary) ; Paclitaxel; Trastuzumab
- Indications Advanced breast cancer
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Daiichi Sankyo Company
- 19 Jul 2017 Planned End Date changed from 30 Nov 2016 to 31 Dec 2018.
- 13 Jun 2016 Planned End Date changed from 30 Nov 2015 to 30 Nov 2016.
- 06 Jul 2015 New source identified and integrated; Japan Pharmaceutical Information Center - Clinical Trials Information record (JapicCTI-121772)